Ritter Pharmaceuticals is discovering a new frontier in human gut health research. Our microbiome modifiers change and enhance the microbial populations in the gastrointestinal tract in order to improve the health of individuals suffering from a variety of metabolic, gastrointestinal, and inflammatory diseases. Microbiome modifiers, or prebiotics, are dietary based gut microbiota management tools that improve health by fortifying beneficial bacteria indigenous to the digestive tract. This technology has expansive promise for the development of numerous products that will treat a variety of conditions and improve digestive health.
The Gut Microbiome
The human gut is a relatively under explored ecosystem but provides a great opportunity for using dietary intervention strategies to reduce the impact of gastrointestinal disease. The human body carries about 100 trillion microorganisms in the intestines, which is ten times great than the number of cells in the human body. This microbial population is responsible for a number of beneficial activities such as fermentation, strengthening the immune system, preventing growth of pathogenic bacteria, providing nutrients, and providing hormones. Recent major initiatives such as the Human Microbiome Project (HMP) by the National Institutes of Health have further validated the significance of the microbial population that exists in our bodies. The increasing knowledge of how these microbial populations impact human health provides opportunities for novel therapies to treat an assortment of diseases. For example: Neurological Disease, Cardiovascular Disease, Obesity, Irritable Bowel Syndrome, Inflammatory Bowel Disease, Colon Cancer, Allergies, Autism & Depression.